Treatment with anti-CD19 bispecific T-cell engager and CAR T therapies can lead to T-cell exhaustion and treatment failure. Novartis AG’s first-in-class anti-CD19, anti-CD3 and anti-CD2 IgG-like trispecific antibody PIT-565, which engages CD19+ on tumor cells, and CD3 (TCR signaling component) and CD2 (a costimulatory receptor) on T cells simultaneously to redirect T-cell cytotoxicity toward CD19-positive malignant B cells, has been designed to avoid T-cell exhaustion.
Starton Therapeutics Inc. has reported findings from a preclinical efficacy study of STAR-LLD, a continuous delivery system of lenalidomide, in a lenalidomide-resistant animal model. The 28-day efficacy study evaluated STAR-LLD continuous subcutaneous (s.c.) infusion versus intraperitoneal (i.p.) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice.
1st Biotherapeutics Inc. has received clearance from the FDA for its IND application to evaluate FB-849, a small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor, in patients with advanced solid tumors.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has patented spiro compounds acting as tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer and cardiovascular and immunological disorders.
Dana-Farber Cancer Institute Inc. and Cornell University have disclosed phosphatidylinositol 5-phosphate 4-kinase type-2 γ (PIP4K2C) inhibitors and its PROTAC compounds reported to be useful for the treatment of cancer, infections, immunodeficiency disorders, insulin resistance, autoimmune and Huntington's disease.
Carina Biotech Pty Ltd. has submitted an IND application to the FDA to conduct a first-in-human phase I/IIa trial of CNA-3103, its LGR5-targeted chimeric antigen receptor T-cell (CAR-T) therapy candidate, in patients with advanced colorectal cancer.
Spexis AG has released results from an in vitro study evaluating the effects of combining its potent CXCR4 inhibitor balixafortide (BLX) with several available conventional or targeted therapies in B-cell lymphoma models.
Onchilles Pharma Inc. has nominated its first drug development candidate, N-17350, a first-in-class biologic therapeutic that is designed to leverage the immunobiology of neutrophils against a wide range of cancer types. Research published last year first described a pathway where human neutrophils release catalytically active neutrophil elastase, called ELANE, to selectively kill many cancer cell types while sparing noncancer cells.
Preliminary preclinical data have been reported for Enliven Therapeutics Inc.’s ATP-competitive small-molecule ABL1 tyrosine kinase inhibitor (TKI) ELVN-001. In vitro antiproliferative effects, assessed using the biomarker Tyr207-phosphorylated CRKL, demonstrated that ELVN-001 had potent activity with IC50 values ranging from 19 to 112 nM against BCR-ABL1-driven chronic myeloid leukemia (CML) cell lines in the presence of 50% to 100% human serum.
Janssen Pharmaceutica NV reported on the company’s novel fully human immunoglobulin G1 CD79bxCD20xCD3 trispecific antibody JNJ-80948543, comprising an anti-CD3 ε single-chain variable fragment (scFv), an anti-CD20 scFv, and an anti-CD79b fragment antigen-binding (Fab) domain and an effector-silent Fc, designed to redirect T cells to treat patients whose disease no longer responds to previous lines of therapy.
RSS
